NewsMV
Daraxonrasib's Phase 3 survival print has put Revolution Medicines (NASDAQ: RVMD) in focus for potential acquirers.
The drug posted 13.2 months median overall survival against 6.7 months for chemotherapy in second-line pancreatic cancer (HR 0.40; p<0.0001), the FDA accepted the NDA and granted Priority Voucher review, and shares closed at $205.55 on August 11, 2026.
The next definitive event is the FDA decision on daraxonrasib. The numbers The stock is up 492.4% over one year, giving Revolution a market cap of $44.1 billion.
The company carries $3.94 billion in liquidity (cash and marketable securities), including $2.23 billion from spring 2026 capital raises and up to an additional $1.5 billion available under Royalty Pharma arrangements.
Keep reading